Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

'Right To Try' Bill Contradicts US FDA’s Mission, Former Official Says

Executive Summary

Heading into the user fee reauthorization cycle, it seems inevitable that some form of federal 'right to try' legislation will tag-along for the ride. The recently departed head of the Office of New Drugs is among those who thinks the innocuous-sounding bill is a very bad idea.

Advertisement

Related Content

Not Quite FDARA Add-Ons: Right-To-Try, Patient Experience, Opioid Measures Also Clear US Senate
'Right To Try' And PDUFA VI: Patient Advocates, Industry Fight Senate Add-On
Gottlieb Nomination As US FDA Chief Could Signal Changes To Generic Approval Process
'Right to Try' Has White House Support: Add-On To PDUFA Looks Tough To Stop
Biogen Spinraza Approval: The Perfect Antidote To Sarepta Headlines?
Jenkins' Retirement From US FDA Was Several Years In The Making
'Right To Try' Or 'Right To Ask'? Hearing Spotlights Adverse Events As Key Barrier To Expanded Access
Expanded Access Programs Need FDA Policy Changes To Really Expand

Topics

Advertisement
UsernamePublicRestriction

Register

PS120228

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel